HIV infection in the brain: a long-term limitation of HAART?
26 April 2009. Related: Conference reports.
Conference reports
When to start HAART – a key research question with the least available data
26 April 2009. Related: Conference reports.
Major studies rule out any benefit of Interleukin-2 (IL-2): results from ESPRIT and SILCAAT
26 April 2009. Related: Conference reports.
Higher rates of non-AIDS cancers in HIV positive people
26 April 2009. Related: Conference reports, Cancer and HIV.
Effect of breast feeding vs formula feeding on maternal health
26 April 2009. Related: Conference reports, Pregnancy.
PEPI-Malawi
26 April 2009. Related: Conference reports, Pregnancy.
Premature delivery and mother-to-child HIV transmission: a risk/benefit analysis among women receiving HAART
20 April 2009. Related: Conference reports, Pregnancy.
Risk factors for adverse pregnancy outcomes in Botswana
20 April 2009. Related: Conference reports, Pregnancy.
Higher risk of transmission with delayed control of maternal viral load despite viral loads of <500 copies/mL at delivery
20 April 2009. Related: Conference reports, Pregnancy.
Lopinavir/r containing regimen superior to nevirapine containing regimen in women previously exposed to single dose nevirapine
20 April 2009. Related: Conference reports, Pregnancy.
Covering the nevirapine tail
20 April 2009. Related: Conference reports, Pregnancy.
Effect of single dose nevirapine on subsequent nevirapine-containing HAART: long term outcomes
20 April 2009. Related: Conference reports, Pregnancy.
High rates of HIV acquisition in pregnancy and post partum in Francistown, Botswana
20 April 2009. Related: Conference reports, Pregnancy.
Children on HAART do extremely well at South African clinic
20 April 2009. Related: Conference reports, Paediatric care.
New boosting alternatives to ritonavir: GS-99350 and SPI-452
20 April 2009. Related: Conference reports.
Interactions with raltegravir: with twice-daily atazanavir and standard dose lamotrigine
20 April 2009. Related: Conference reports.
Effect of tenofovir on abacavir phosphorylation
20 April 2009. Related: Conference reports, PK and drug interactions.
Nevirapine: fluconazole and TB treatment
20 April 2009. Related: Conference reports, TB coinfection.
PI interactions: lopinavir/rifampicin, saquinavir, atazanavir/tenofovir in pregnancy
20 April 2009. Related: Conference reports, PK and drug interactions.
Identification of drug interactions in clinical practice
20 April 2009. Related: Conference reports.
Effect of substance abuse on ART pharmacokinetics
20 April 2009. Related: Conference reports.
9th International Congress on Drug Therapy in HIV Infection, 9-13 November 2008, Glasgow
18 February 2009. Related: Conference reports.
Summary of antiretroviral studies at Glasgow
18 February 2009. Related: Conference reports, Antiretrovirals.
The Antiretroviral Pregnancy Registry: individual drug safety reports on health of infants exposed to ARVs during pregnancy
18 February 2009. Related: Conference reports.
Initial results from PENTA 11 trial of planned treatment interruption
18 February 2009. Related: Conference reports.
Inflammation and coagulation markers askew in children with higher HIV RNA
18 February 2009. Related: Conference reports.
Dosing of lopinavir/ritonavir in the CHIPS cohort
18 February 2009. Related: Conference reports.
Number needed to treat to harm (NNTH) analysis of impact of underlying cardiovascular factors on risk of abacavir-related heart attack
18 February 2009. Related: Conference reports.
Bone disease and HIV
18 February 2009. Related: Conference reports.
Renal tubule damage with tenofovir despite normal glomerular function
18 February 2009. Related: Conference reports.
10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 6-8 November 2008, London, UK
18 February 2009. Related: Conference reports.
Report from the 10th IWADRLH by Jacqueline Capeau
18 February 2009. Related: Conference reports.
Report from the 10th IWADRLH by Michael Dubé
18 February 2009. Related: Conference reports.
Impact of body changes on the quality of life of HIV-positive treatment-experienced patients: an online community-based survey
18 February 2009. Related: Conference reports.
48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington DC
27 December 2008. Related: Conference reports.
Antiretroviral Pregnancy Registry finds no increase in congenital anomalies with exposure to tenofovir
27 December 2008. Related: Conference reports, Pregnancy.
No association between maternal antiretrovirals in pregnancy and congenital anomalies
27 December 2008. Related: Conference reports, Pregnancy.
Pharmacokinetics of saquinavir/ritonavir in pregnancy
27 December 2008. Related: Conference reports, Pregnancy.
Course of labour in pregnant HIV-positive women with no contraindication for vaginal delivery
27 December 2008. Related: Conference reports, Pregnancy.
Four weeks of antiretroviral prophylaxis is sufficient for HIV-exposed infants
27 December 2008. Related: Conference reports, Pregnancy.
HAART suppresses genital tract HIV shedding in HIV/HSV co-infected women
27 December 2008. Related: Conference reports, Women's health.
Efavirenz significantly reduces levels of some oral contraceptives
27 December 2008. Related: Conference reports, Women's health.
Lack of efficacy of isoniazid (INH) prophylaxis and PK evaluation in South African infants
27 December 2008. Related: Conference reports, Paediatric care, TB coinfection.
48-week data for darunavir/ritonavir (DRV/r) in treatment-experienced children and adolescents
26 December 2008. Related: Conference reports, Paediatric care.
Greater lipodystrophy risk in older US children with low viral load
26 December 2008. Related: Conference reports, Paediatric care.
Studies of pipeline drugs: RDEA806, PRO140, bevirimat, elvucitabine
26 December 2008. Related: Conference reports, Antiretrovirals.
Maraviroc trial results reanalysed using more sensitive CCR5 tropism test
26 December 2008. Related: Conference reports.
Other antiretroviral studies at ICAAC
26 December 2008. Related: Conference reports, Antiretrovirals.
High rate of rash in HIV negative volunteers combining raltegravir and darunavir
26 December 2008. Related: Conference reports, Side effects.
Bone loss in SMART study
26 December 2008. Related: Conference reports, Side effects.
Parathyroid hormone and vitamin D levels in patients using tenofovir
26 December 2008. Related: Conference reports, Side effects.
Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy
26 December 2008. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Statin use in HIV-positive patients
26 December 2008. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
HIV reinfection reported in 10% of couples in Zambian study
26 December 2008. Related: Conference reports, HIV prevention and transmission.
Drug interaction studies with approved drugs
26 December 2008. Related: Conference reports, PK and drug interactions.
Non alcoholic fatty liver disease (NAFLD) is common among HIV-positive patients
26 December 2008. Related: Conference reports, Antiretrovirals.
17th International AIDS Conference, 3-8 August 2008, Mexico City
30 October 2008. Related: Conference reports.
Abacavir and heart disease: SMART study supports an abacavir-associated increased risk of cardiovascular disease
30 October 2008. Related: Conference reports, Antiretrovirals, Side effects.
HAART use in pregnancy and preterm delivery and low birth weight
30 October 2008. Related: Conference reports, Pregnancy.
Reasons for mother to child transmission in England
30 October 2008. Related: Conference reports, Pregnancy.
New paediatric formulations of ARVs
30 October 2008. Related: Conference reports, Paediatric care.
3rd International Transmission Workshop, 1-2 August 2008, Mexico City
30 October 2008. Related: Conference reports.
Intermittent tenofovir/FTC PrEP offers monkeys some protection
30 October 2008. Related: Conference reports, HIV prevention and transmission.
Tenofovir/FTC gel protects female monkeys from SHIV
30 October 2008. Related: Conference reports, HIV prevention and transmission.
Recently infected HIV-positive Quebec residents cause more than half of new cases
30 October 2008. Related: Conference reports, HIV prevention and transmission.